Cenobamate Dosing and Safety Protocol
Start cenobamate at 12.5 mg once daily and titrate every 2 weeks following the FDA-mandated schedule to reach the target maintenance dose of 200 mg daily, with a maximum of 400 mg daily if needed—this slow titration is critical to prevent DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), which has resulted in fatalities with faster titration schedules. 1
Mandatory Titration Schedule
The FDA-approved titration regimen must not be exceeded 1:
- Weeks 1-2: 12.5 mg once daily
- Weeks 3-4: 25 mg once daily
- Weeks 5-6: 50 mg once daily
- Weeks 7-8: 100 mg once daily
- Weeks 9-10: 150 mg once daily
- Week 11 onward: 200 mg once daily (maintenance dose)
- Maximum dose: 400 mg once daily (increase by 50 mg every 2 weeks above 200 mg if needed)
This 12-week titration to 200 mg is non-negotiable. An open-label safety study of 1,339 patients demonstrated zero cases of DRESS when this schedule was followed, whereas DRESS occurred (including one death) with weekly or faster titration 1. The evidence is clear: slower titration prevents life-threatening hypersensitivity reactions.
Administration Details
Cenobamate can be taken with or without food, once daily 1. Tablets may be swallowed whole or crushed and mixed with 25 mL water for oral administration or nasogastric tube delivery 1. The crushed mixture must be consumed immediately and not stored.
Critical Safety Precautions
DRESS/Multiorgan Hypersensitivity (Black Box Concern)
Discontinue cenobamate immediately if DRESS is suspected and no alternative etiology exists 1. Monitor for fever, rash, lymphadenopathy, facial swelling, and organ dysfunction (hepatic, renal, hematologic). This is the most serious safety concern and the reason the titration schedule cannot be accelerated.
QT Shortening
Cenobamate is contraindicated in patients with Familial Short QT syndrome 1. Use caution when combining with other QT-shortening drugs. This represents a unique cardiac safety consideration not seen with most antiseizure medications.
Drug Interactions Requiring Proactive Management
The pharmacokinetic profile of cenobamate demands specific dose adjustments 2, 3:
Reduce these concomitant medications:
- Phenytoin: Decrease by up to 50% 1
- Phenobarbital and clobazam: Reduce as needed; expert consensus suggests maintaining clobazam at 5-10 mg may be beneficial 3
- CYP2C19 substrates: Reduce doses as needed 1
Increase these concomitant medications:
- Lamotrigine and carbamazepine: Increase as needed 1
- CYP2B6 and CYP3A substrates: Increase as needed 1
Special considerations:
- Oral contraceptives: Effectiveness may be reduced; patients must use additional or alternative non-hormonal birth control 1
- Sodium channel blockers (SCBs): If the patient is on ≥2 SCBs, proactive down-titration or withdrawal of one SCB is recommended to minimize CNS adverse effects 3
Common Adverse Events
The most frequent treatment-emergent adverse events (≥10%) include somnolence, dizziness, fatigue, diplopia, and headache 1, 4. These are dose-related and typically emerge early (Week 1 onward) but often resolve with continued treatment 5. Higher rates of adverse events occur when cenobamate is combined with other sodium channel blockers 2.
Warn patients not to drive or operate machinery until they understand how cenobamate affects them 1. Concomitant use with other CNS depressants or alcohol has additive effects 1.
Dosage Modifications for Special Populations
Hepatic Impairment
- Mild to moderate (Child-Pugh A-B): Maximum dose 200 mg daily 1
- Severe (Child-Pugh C): Not recommended 1
Renal Impairment
Use with caution in mild to moderate renal impairment (CrCl 30-90 mL/min) and severe impairment (CrCl <30 mL/min); dosage reduction may be considered. Not recommended in end-stage renal disease requiring dialysis 1.
Discontinuation Protocol
Taper cenobamate gradually over at least 2 weeks when discontinuing to minimize seizure frequency increase 1. Abrupt withdrawal should only occur if safety concerns mandate it (e.g., DRESS, severe hypersensitivity) 1.
Efficacy Timeline
Patients may experience meaningful seizure reduction early during titration. In clinical trials, statistically significant reductions in seizure frequency occurred by Weeks 5-6 (at 50 mg dose: 42.9% median reduction vs 15.4% placebo) and Weeks 7-8 (at 100 mg dose: 55.6% reduction vs 20% placebo) 6. Seizure-free rates of 26.7% were observed as early as Weeks 7-8 6. This suggests that clinical response assessment at the 100 mg dose (Week 8) is reasonable, as recommended by expert consensus 3.
However, maximal efficacy occurs at higher doses. In pivotal trials, seizure-free rates during maintenance phases were 12.4%, 30.1%, and 52.4% for 100,200, and 400 mg daily, respectively 7. The 200 mg target dose achieved 56% responder rates (≥50% seizure reduction) in one study 8, while 400 mg achieved 64% responder rates and median seizure reductions of 100% in Asian populations 7.
Clinical Pitfalls to Avoid
- Never accelerate titration beyond the FDA schedule, regardless of seizure severity—DRESS risk is unacceptable
- Proactively adjust interacting medications rather than waiting for adverse events or loss of efficacy
- Counsel about contraceptive failure before initiating treatment in women of childbearing potential
- Screen for Familial Short QT syndrome and review QT-shortening medications before prescribing
- Evaluate concomitant sodium channel blockers—if ≥2 are present, plan to reduce one during cenobamate titration 3
- Monitor patients with intellectual disabilities more closely as they may need additional support navigating the titration period 3
The evidence base for cenobamate is robust, with multiple randomized controlled trials 8, 7 and real-world studies 9 demonstrating exceptional efficacy (including remarkably high seizure-free rates) when the proper titration schedule and drug interaction management are followed.